In addition, prostate-specific membrane antigen (PSMA), which is expressed in prostate cancer cells, can be used to specifically target therapies such as LU-PSMA radioligand therapy [4] or PSMA BiTE—a bispecific CD3 and PSMA antibody that redirects T-cells to PSMA-expressing cells (reviewed in [1,3]). This evidence concerns the gene FOLH1 and prostate carcinoma.